Concepts (219)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| MicroRNAs | 40 | 2023 | 426 | 8.050 |
Why?
|
| Neoplasms | 19 | 2021 | 1103 | 3.420 |
Why?
|
| Gene Expression Regulation, Neoplastic | 22 | 2021 | 807 | 2.930 |
Why?
|
| Exosomes | 6 | 2018 | 101 | 1.870 |
Why?
|
| Killer Cells, Natural | 3 | 2021 | 92 | 1.470 |
Why?
|
| Neuroblastoma | 3 | 2021 | 129 | 1.270 |
Why?
|
| Cell Communication | 5 | 2021 | 97 | 1.120 |
Why?
|
| RNA, Untranslated | 5 | 2019 | 42 | 1.100 |
Why?
|
| Epigenesis, Genetic | 4 | 2018 | 219 | 0.990 |
Why?
|
| Toll-Like Receptors | 2 | 2013 | 51 | 0.860 |
Why?
|
| RNA | 2 | 2023 | 241 | 0.850 |
Why?
|
| Conserved Sequence | 4 | 2017 | 119 | 0.850 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 2 | 2017 | 88 | 0.830 |
Why?
|
| Immunotherapy | 2 | 2021 | 95 | 0.830 |
Why?
|
| Lung Neoplasms | 4 | 2017 | 358 | 0.790 |
Why?
|
| Humans | 50 | 2023 | 37093 | 0.720 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 5 | 2011 | 15 | 0.670 |
Why?
|
| Genome, Human | 2 | 2010 | 135 | 0.660 |
Why?
|
| RNA, Neoplasm | 4 | 2013 | 26 | 0.650 |
Why?
|
| DNA Methylation | 4 | 2018 | 325 | 0.610 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2016 | 222 | 0.570 |
Why?
|
| Genes, Tumor Suppressor | 5 | 2017 | 63 | 0.560 |
Why?
|
| Leukemia | 4 | 2010 | 56 | 0.560 |
Why?
|
| Animals | 24 | 2021 | 15081 | 0.520 |
Why?
|
| Neoplasm Proteins | 1 | 2016 | 213 | 0.500 |
Why?
|
| Cell Proliferation | 8 | 2018 | 1198 | 0.460 |
Why?
|
| Monocytes | 1 | 2015 | 257 | 0.440 |
Why?
|
| Proteins | 2 | 2019 | 369 | 0.430 |
Why?
|
| Cell Transformation, Neoplastic | 2 | 2016 | 172 | 0.430 |
Why?
|
| Gene Expression Profiling | 6 | 2010 | 626 | 0.390 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 4 | 2010 | 306 | 0.380 |
Why?
|
| Genes, p53 | 1 | 2011 | 25 | 0.380 |
Why?
|
| Chromosome Deletion | 1 | 2011 | 56 | 0.370 |
Why?
|
| Hematopoietic System | 1 | 2010 | 3 | 0.360 |
Why?
|
| Xenograft Model Antitumor Assays | 5 | 2018 | 259 | 0.360 |
Why?
|
| Oncogenes | 3 | 2008 | 43 | 0.340 |
Why?
|
| Lymphoma | 1 | 2009 | 38 | 0.330 |
Why?
|
| Mice | 13 | 2021 | 5913 | 0.330 |
Why?
|
| Tumor Escape | 2 | 2019 | 13 | 0.320 |
Why?
|
| Genomics | 1 | 2010 | 223 | 0.320 |
Why?
|
| Inflammation | 1 | 2013 | 618 | 0.310 |
Why?
|
| RNA, Small Interfering | 1 | 2010 | 409 | 0.310 |
Why?
|
| Cell Line, Tumor | 7 | 2021 | 2231 | 0.300 |
Why?
|
| DNA, Neoplasm | 1 | 2007 | 92 | 0.300 |
Why?
|
| Genetic Variation | 1 | 2009 | 387 | 0.280 |
Why?
|
| Signal Transduction | 1 | 2015 | 1908 | 0.270 |
Why?
|
| Prognosis | 6 | 2011 | 739 | 0.250 |
Why?
|
| RNA, Messenger | 2 | 2009 | 1207 | 0.250 |
Why?
|
| CD8-Positive T-Lymphocytes | 2 | 2021 | 159 | 0.220 |
Why?
|
| Mutation | 5 | 2008 | 1095 | 0.220 |
Why?
|
| Lung | 3 | 2017 | 446 | 0.200 |
Why?
|
| Ligands | 2 | 2013 | 349 | 0.200 |
Why?
|
| Mice, Nude | 4 | 2017 | 337 | 0.200 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2021 | 20 | 0.190 |
Why?
|
| Transcription, Genetic | 4 | 2013 | 578 | 0.190 |
Why?
|
| Base Sequence | 4 | 2017 | 997 | 0.190 |
Why?
|
| Drug Discovery | 2 | 2013 | 82 | 0.190 |
Why?
|
| Mice, Inbred NOD | 2 | 2018 | 45 | 0.190 |
Why?
|
| Immunologic Factors | 1 | 2021 | 45 | 0.190 |
Why?
|
| Clinical Trials as Topic | 2 | 2019 | 204 | 0.190 |
Why?
|
| Chromosomes, Human, Pair 17 | 2 | 2011 | 10 | 0.190 |
Why?
|
| Mice, SCID | 2 | 2018 | 150 | 0.190 |
Why?
|
| Neoplasm Invasiveness | 3 | 2016 | 251 | 0.190 |
Why?
|
| Tumor Cells, Cultured | 2 | 2018 | 502 | 0.180 |
Why?
|
| Down-Regulation | 4 | 2017 | 435 | 0.180 |
Why?
|
| Apoptosis | 5 | 2018 | 1398 | 0.180 |
Why?
|
| Transplantation, Homologous | 1 | 2019 | 36 | 0.180 |
Why?
|
| Female | 13 | 2023 | 20969 | 0.180 |
Why?
|
| Disease Progression | 2 | 2021 | 601 | 0.170 |
Why?
|
| Chromosomes, Human, Pair 13 | 2 | 2011 | 11 | 0.160 |
Why?
|
| Nucleic Acid Conformation | 1 | 2019 | 146 | 0.160 |
Why?
|
| Myelodysplastic-Myeloproliferative Diseases | 1 | 2018 | 1 | 0.160 |
Why?
|
| Chromosome Aberrations | 2 | 2010 | 60 | 0.160 |
Why?
|
| Cisplatin | 2 | 2016 | 72 | 0.160 |
Why?
|
| Gene Expression Regulation, Leukemic | 2 | 2009 | 8 | 0.160 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2018 | 93 | 0.160 |
Why?
|
| Colorectal Neoplasms | 2 | 2015 | 441 | 0.160 |
Why?
|
| Gastrointestinal Diseases | 1 | 2018 | 42 | 0.150 |
Why?
|
| Cyclins | 1 | 2017 | 37 | 0.150 |
Why?
|
| Treatment Outcome | 2 | 2019 | 1369 | 0.140 |
Why?
|
| Promoter Regions, Genetic | 2 | 2010 | 515 | 0.140 |
Why?
|
| Antineoplastic Agents | 2 | 2015 | 803 | 0.140 |
Why?
|
| Lymphatic Metastasis | 1 | 2016 | 65 | 0.140 |
Why?
|
| Up-Regulation | 2 | 2017 | 513 | 0.140 |
Why?
|
| RNA Transport | 1 | 2016 | 1 | 0.140 |
Why?
|
| Viruses | 1 | 2016 | 36 | 0.140 |
Why?
|
| DNA | 1 | 2019 | 574 | 0.140 |
Why?
|
| Biological Transport | 1 | 2016 | 185 | 0.140 |
Why?
|
| Stromal Cells | 1 | 2016 | 49 | 0.140 |
Why?
|
| Lymphocytes | 1 | 2016 | 118 | 0.140 |
Why?
|
| Immune System | 1 | 2016 | 41 | 0.140 |
Why?
|
| Dendritic Cells | 1 | 2016 | 113 | 0.140 |
Why?
|
| Immunity, Innate | 1 | 2016 | 149 | 0.130 |
Why?
|
| Breast Neoplasms | 2 | 2023 | 1502 | 0.130 |
Why?
|
| Models, Molecular | 1 | 2019 | 808 | 0.130 |
Why?
|
| Sepsis | 1 | 2016 | 80 | 0.130 |
Why?
|
| Toll-Like Receptor 8 | 1 | 2015 | 3 | 0.130 |
Why?
|
| Receptor Cross-Talk | 1 | 2015 | 17 | 0.130 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2016 | 63 | 0.130 |
Why?
|
| Telomere-Binding Proteins | 1 | 2015 | 12 | 0.130 |
Why?
|
| Neovascularization, Pathologic | 1 | 2016 | 127 | 0.130 |
Why?
|
| Adenocarcinoma | 2 | 2015 | 251 | 0.130 |
Why?
|
| Coculture Techniques | 1 | 2015 | 101 | 0.130 |
Why?
|
| Macrophages | 2 | 2016 | 439 | 0.130 |
Why?
|
| Cell Differentiation | 2 | 2009 | 587 | 0.120 |
Why?
|
| Male | 9 | 2018 | 20025 | 0.120 |
Why?
|
| Chromosomes, Human, Pair 11 | 2 | 2011 | 15 | 0.120 |
Why?
|
| ZAP-70 Protein-Tyrosine Kinase | 2 | 2011 | 3 | 0.110 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 2016 | 213 | 0.110 |
Why?
|
| Models, Biological | 2 | 2013 | 677 | 0.110 |
Why?
|
| Aged | 6 | 2018 | 6741 | 0.110 |
Why?
|
| NF-kappa B | 1 | 2015 | 339 | 0.100 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 3 | 2023 | 623 | 0.090 |
Why?
|
| Histone Code | 1 | 2010 | 13 | 0.090 |
Why?
|
| Middle Aged | 6 | 2018 | 10129 | 0.090 |
Why?
|
| Models, Genetic | 1 | 2010 | 172 | 0.090 |
Why?
|
| CpG Islands | 1 | 2010 | 97 | 0.090 |
Why?
|
| Genetic Testing | 1 | 2010 | 75 | 0.090 |
Why?
|
| Principal Component Analysis | 1 | 2010 | 89 | 0.090 |
Why?
|
| Protein Binding | 1 | 2012 | 972 | 0.090 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2009 | 30 | 0.090 |
Why?
|
| Histone Deacetylases | 1 | 2010 | 56 | 0.090 |
Why?
|
| Adaptation, Biological | 1 | 2009 | 24 | 0.080 |
Why?
|
| Cytokines | 1 | 2013 | 602 | 0.080 |
Why?
|
| Chromatin | 1 | 2010 | 169 | 0.080 |
Why?
|
| Neoplasm Metastasis | 1 | 2010 | 219 | 0.080 |
Why?
|
| Histones | 1 | 2010 | 190 | 0.080 |
Why?
|
| Cytogenetics | 1 | 2008 | 3 | 0.080 |
Why?
|
| Leukemia, Erythroblastic, Acute | 1 | 2008 | 10 | 0.080 |
Why?
|
| Multigene Family | 1 | 2008 | 106 | 0.080 |
Why?
|
| Shock, Septic | 1 | 2007 | 20 | 0.080 |
Why?
|
| Gene Amplification | 1 | 2007 | 26 | 0.080 |
Why?
|
| Translocation, Genetic | 1 | 2007 | 42 | 0.070 |
Why?
|
| Cell Hypoxia | 1 | 2007 | 58 | 0.070 |
Why?
|
| Binding Sites | 1 | 2009 | 651 | 0.070 |
Why?
|
| Protein Biosynthesis | 1 | 2008 | 133 | 0.070 |
Why?
|
| Aged, 80 and over | 4 | 2018 | 2379 | 0.070 |
Why?
|
| Embryonic Stem Cells | 1 | 2007 | 59 | 0.070 |
Why?
|
| Polymorphism, Genetic | 1 | 2008 | 191 | 0.070 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2007 | 168 | 0.070 |
Why?
|
| Carcinoma | 1 | 2007 | 96 | 0.070 |
Why?
|
| Survival Analysis | 1 | 2007 | 325 | 0.070 |
Why?
|
| Gene Expression | 2 | 2009 | 674 | 0.070 |
Why?
|
| Adult | 5 | 2018 | 11712 | 0.070 |
Why?
|
| Lipopolysaccharides | 1 | 2007 | 220 | 0.070 |
Why?
|
| Oxidoreductases | 1 | 2006 | 87 | 0.070 |
Why?
|
| Immunoglobulin Heavy Chains | 1 | 2005 | 62 | 0.070 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2007 | 356 | 0.060 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2009 | 628 | 0.060 |
Why?
|
| Phenotype | 1 | 2008 | 689 | 0.060 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2005 | 132 | 0.060 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2005 | 152 | 0.060 |
Why?
|
| Reproducibility of Results | 2 | 2023 | 935 | 0.060 |
Why?
|
| Genetic Markers | 2 | 2018 | 142 | 0.060 |
Why?
|
| Transfection | 3 | 2012 | 523 | 0.060 |
Why?
|
| Estrogen Receptor alpha | 1 | 2023 | 111 | 0.050 |
Why?
|
| Predictive Value of Tests | 2 | 2015 | 400 | 0.050 |
Why?
|
| Mice, Transgenic | 2 | 2018 | 617 | 0.050 |
Why?
|
| Estrogens | 1 | 2023 | 202 | 0.050 |
Why?
|
| Estradiol | 1 | 2023 | 262 | 0.050 |
Why?
|
| Cell Movement | 2 | 2016 | 571 | 0.050 |
Why?
|
| Karyotyping | 2 | 2010 | 47 | 0.040 |
Why?
|
| Genetic Heterogeneity | 1 | 2018 | 9 | 0.040 |
Why?
|
| T-Lymphocytes | 1 | 2021 | 357 | 0.040 |
Why?
|
| Blotting, Northern | 2 | 2009 | 150 | 0.040 |
Why?
|
| RNA Editing | 1 | 2018 | 36 | 0.040 |
Why?
|
| Prostatic Neoplasms | 1 | 2006 | 935 | 0.040 |
Why?
|
| Molecular Mimicry | 1 | 2016 | 16 | 0.040 |
Why?
|
| Austria | 1 | 2015 | 4 | 0.030 |
Why?
|
| Romania | 1 | 2015 | 6 | 0.030 |
Why?
|
| Neoplasm Staging | 1 | 2016 | 275 | 0.030 |
Why?
|
| Italy | 1 | 2015 | 22 | 0.030 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2018 | 767 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 2015 | 562 | 0.030 |
Why?
|
| NM23 Nucleoside Diphosphate Kinases | 1 | 2012 | 2 | 0.030 |
Why?
|
| HCT116 Cells | 1 | 2012 | 35 | 0.030 |
Why?
|
| Receptors, Interleukin-2 | 1 | 2012 | 32 | 0.030 |
Why?
|
| Cyclin D1 | 1 | 2012 | 43 | 0.030 |
Why?
|
| Tumor Burden | 1 | 2012 | 77 | 0.030 |
Why?
|
| Homeodomain Proteins | 1 | 2012 | 132 | 0.020 |
Why?
|
| RNA Interference | 1 | 2012 | 243 | 0.020 |
Why?
|
| Nucleotide Mapping | 1 | 2010 | 3 | 0.020 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2010 | 53 | 0.020 |
Why?
|
| Gene Dosage | 1 | 2010 | 75 | 0.020 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2010 | 39 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2012 | 933 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2012 | 1130 | 0.020 |
Why?
|
| Blood Cell Count | 1 | 2008 | 14 | 0.020 |
Why?
|
| Trisomy | 1 | 2008 | 10 | 0.020 |
Why?
|
| Antigens, CD34 | 1 | 2008 | 19 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 8 | 1 | 2008 | 27 | 0.020 |
Why?
|
| Jurkat Cells | 1 | 2007 | 79 | 0.020 |
Why?
|
| Cell Lineage | 1 | 2008 | 90 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2009 | 859 | 0.020 |
Why?
|
| Time Factors | 1 | 2012 | 1742 | 0.020 |
Why?
|
| Cluster Analysis | 1 | 2007 | 195 | 0.020 |
Why?
|
| Sequence Analysis, RNA | 1 | 2007 | 106 | 0.020 |
Why?
|
| Proteome | 1 | 2008 | 144 | 0.020 |
Why?
|
| Stem Cells | 1 | 2008 | 141 | 0.020 |
Why?
|
| Hematologic Neoplasms | 1 | 2006 | 16 | 0.020 |
Why?
|
| Transduction, Genetic | 1 | 2006 | 19 | 0.020 |
Why?
|
| Cell Growth Processes | 1 | 2006 | 41 | 0.020 |
Why?
|
| Adenoviridae | 1 | 2006 | 62 | 0.020 |
Why?
|
| Transplantation, Heterologous | 1 | 2006 | 90 | 0.020 |
Why?
|
| Neoplasm Transplantation | 1 | 2006 | 122 | 0.020 |
Why?
|
| Gene Rearrangement | 1 | 2005 | 15 | 0.020 |
Why?
|
| Immunoglobulin Variable Region | 1 | 2005 | 25 | 0.020 |
Why?
|
| Genes, Immunoglobulin | 1 | 2005 | 41 | 0.020 |
Why?
|
| Proteomics | 1 | 2008 | 325 | 0.020 |
Why?
|
| Point Mutation | 1 | 2005 | 93 | 0.020 |
Why?
|
| Germ-Line Mutation | 1 | 2005 | 57 | 0.020 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2006 | 194 | 0.020 |
Why?
|
| Molecular Sequence Data | 1 | 2007 | 1568 | 0.010 |
Why?
|
| Cell Line | 1 | 2007 | 1354 | 0.010 |
Why?
|
| Sequence Analysis, DNA | 1 | 2005 | 474 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2007 | 1518 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2007 | 1609 | 0.010 |
Why?
|
| Risk Factors | 1 | 2010 | 3562 | 0.010 |
Why?
|
| Adolescent | 1 | 2008 | 5363 | 0.010 |
Why?
|